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Abstract
Introduction: Dectin-1, a pattern recognition receptor expressed by the innate immune system, is known to be a
major receptor inducing Th17-type adaptive immune responses that have been demonstrated to mediate
autoimmunity. In this study, dectin-1 mRNA and protein expression, as well as the recently characterized DECTIN-1
Y238X early stop codon polymorphism, were studied in relation to rheumatoid arthritis (RA) susceptibility and
severity.
Methods: Dectin-1 mRNA expression was measured in synovial tissue specimens of RA, osteoarthritis (OA), and
nonrheumatic patients. Dectin-1 protein expression and localization were assessed in RA synovial tissue specimens.
Macrophages from individuals with different DECTIN-1 genotypes were examined for differences in cytokine
responses on dectin-1 stimulation. Furthermore, clinical parameters of inflammation and bone destruction of 262
RA patients were correlated with the presence of the DECTIN-1 Y238X polymorphism.
Results: Evaluation of dectin-1 mRNA expression in synovial tissue biopsies revealed an increased expression in RA
specimens, compared with biopsies from OA and nonrheumatic patients. Accordingly, dectin-1 protein expression
in RA synovial tissue biopsies was moderate to high, especially on macrophage-like cells. Cytokine production
capacity of macrophages bearing the DECTIN-1 Y238X polymorphism was demonstrated to be impaired on dectin-
1 stimulation. However, the presence of the DECTIN-1 Y238X polymorphism was not associated with RA
susceptibility or disease severity.
Conclusions: Although expression of dectin-1 was high in synovial tissue of RA patients, and reduced cytokine
production was observed in macrophages of individuals bearing the DECTIN-1 Y238X polymorphism, loss of one
functional allele of DECTIN-1 is not associated with either susceptibility to or severity of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disorder that results in severe cartilage damage and
bone destruction in synovial joints. Despite unclear dis-
ease etiology, it is commonly appreciated that both
genetic and environmental factors are underlying risk
factors in the pathogenesis of RA. In recent years, an
important role for innate immune receptors in RA has
emerged, especially focused on members of the Toll-like
receptor (TLR) family [1,2]. These innate responses
were recently suggested to modulate and induce the
autoimmune-related Th17 responses [3,4].
A different class of innate immune receptors involved
in microbial recognition and subsequent immune signal-
ling are C-type lectins, of which dectin-1 is one of the
most well characterized members. After its discovery as
a receptor for fungal-derived 1,3-b-glucans [5], its intra-
cellular signalling has been demonstrated to be mediated
by Raf-1 and Syk-CARD9 dependent pathways to induce
production of pro-inflammatory cytokines and reactive
oxygen species [6-10]. Other studies have uncovered
that dectin-1 converges with TLR signalling [11,12] for
the induction of cytokine responses and is able to
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promote Th17 and cytotoxic T-cell responses through
activation of dendritic cells [13,14]. It has been well
established that fungal particles, either intact yeast or
fungal cell wall components that can be recognized by
dectin-1, such as zymosan, can act as adjuvants in sev-
eral experimental models of RA [15-19]. In addition, a
study by Yoshitomi and colleagues [20] revealed that b-
glucan induced autoimmune arthritis in genetically sus-
ceptible SKG mice could be prevented by blocking the
dectin-1 receptor.
These studies imply that dectin-1 plays a pivotal role in
the innate immune system and is able to modulate adap-
tive immune responses, of which, especially Th17
responses are implicated in immunopathology. Further-
more, dectin-1 is involved in the induction of arthritis in
mouse models through induction of intracellular signal-
ling on recognition of fungal components. As a conse-
quence, dectin-1 mediated inflammatory responses could
contribute to the aetiology or disease severity of RA.
Recently we characterized an early stop codon poly-
morphism Y238X (c.714T>G, rs16910526) in DECTIN-1
[21], which was demonstrated to result in a complete
loss of function of the protein. Cytokine production
capacity of peripheral blood mononuclear cells (PBMCs)
from individuals homozygous for the DECTIN-1 Y238X
polymorphism on b-glucan or Candida albicans expo-
sure are impaired, including TNF-a, interleukin (IL-)1b,
IL-6, and IL-17 responses. In the same stimulation
assays, individuals heterozygous for the DECTIN-1
Y238X polymorphism exhibited intermediate cytokine
responses compared with wild-type individuals [22].
Considering both the involvement of dectin-1 in pro-
inflammatory responses and the significant conse-
quences of the Y238X polymorphism for dectin-1
function, it is compelling to assess whether dectin-1
and the DECTIN-1 Y238X polymorphism play a role in
the pathogenesis or disease severity of RA. In the pre-
sent study, mRNA expression of dectin-1 was assessed
in synovial tissue biopsies obtained from RA patients
and compared with synovial tissue specimens from
osteoarthritis (OA) patients and from patients with
other underlying joint pathology not related to RA. In
addition, dectin-1 protein expression was assessed in
tissue sections of synovial lesions obtained from RA
patients. The functional consequences of the presence
of the DECTIN-1 Y238X polymorphism on cytokine
production capacity of macrophages were studied by
stimulating the cells with b-glucans. Furthermore, the
presence of the DECTIN-1 Y238X polymorphism was
correlated with disease susceptibility in a cohort of 262
RA patients, and within this cohort, clinical parameters
of joint inflammation and bone destruction were com-
pared after stratifying for the DECTIN-1 genotype.
Materials and methods
Patients
For assessing the effect of the DECTIN-1 Y238X poly-
morphism on the disease course, patient data were used
from the early RA inception cohort at our clinic,
described in more detail elsewhere [23]. Patients were
included in this cohort if they fulfilled the ACR (Ameri-
can College of Rheumatology) classification criteria for
RA, were at least 18 years old, had a disease duration
not exceeding 1 year, and did not use DMARDs or bio-
logic response modifiers. Age, gender, and IgM rheuma-
toid factor were determined at baseline. At baseline and
every 3 months thereafter, patients were assessed by
specialized research nurses who assigned joint inflam-
mation scores and drew a blood sample for determina-
tion of the erythrocyte sedimentation rate. The patients
indicated their global disease activity on a Visual Analo-
gue Scale. These data were used to calculate the disease
activity score (DAS28) according to the original formula
[24]. Radiographs of the hand and feet were made at
baseline, year 1, 2, and 3, and every third year thereafter.
Radiographs of hands and feet were read in chronologic
order by one of four raters, according to the Ratingen
score by using reference pictures [25]. The Ratingen
score (range, 0-190) is a modification of the Larsen
score and evaluates joint surface destruction, graded
from 0 to 5, in 38 hand and feet joints, separately. The
interrater reliability was ICC = 0.85, tested previously
with the four raters in 10 patients over 9 years. Clinical
data were entered in a computerized database.
From 2006 to 2008, additional blood was collected in
a convenience sample of the cohort, used for genotyping
for the DECTIN-1 Y238X polymorphism. For the cur-
rent study, data from cohort patients were included if a
blood sample was available with a joint damage assess-
ment at year 3.
Consequently, 262 patients were included. The study
was approved by our institutional review board, and
informed consent of the patients was obtained before
enrollment. The study was performed according to the
principles of the Declaration of Helsinki.
RNA isolation from synovial tissue
Synovial tissue samples of RA, OA, and nonrheumatic
patients were dissected during surgery or by fine needle
arthroscopy under camera supervision. The tissue sam-
ples were stored at a tissue bank under liquid nitrogen
until further processing. Total RNA was isolated and
purified on an affinity resin (RNeasy Kit for fibrous tis-
sues, Qiagen, Valencia, CA, USA) according to the man-
ufacturer’s instructions. Quantity and purity were
assessed by using Agilent bioanalyzer (Agilent Technol-
ogies, Santa Clara, CA, USA), and integrity, by using
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nanodrop (Thermo Scientific, Waltham, MA, USA)
according to the manufacturer’s instructions. Total RNA
was stored at -80°C until further processing.
Oligonucleotide array
To measure dectin-1 mRNA expression, 100 ng of total
RNA was used as starting material for cDNA prepara-
tion. A two cycle amplification protocol was followed.
Generation of biotinylated cRNA and subsequent hybri-
dization to U133Plus 2.0 oligonucleotide arrays (Affyme-
trix, Santa Clara, CA, USA), washing, and staining were
performed according to Affymetrix Expression Analysis
Technical Manual for two cycle amplification [26]. The
arrays were then scanned by using a laser scanner Gene-
Chip® Scanner (Affymetrix) and analyzed by using Affy-
metrix GeneChip Operating Software (GCOS version
1.4) according to the manufacturer’s instructions. Array
normalization and model-based calculation of expression
values were performed by using DNA-Chip Analyzer
(dChip) version 1.3 [27]. The Invariant Set Normaliza-
tion method and the model based method were used for
computing expression values [28]. These values were
expressed as mean and standard error (SE).
Quantitative RealTime PCR
RNA samples were reverse transcribed by using oligo-
dT primers and MMLV reverse transcriptase. Primers
were designed with Primer Express (Applied Biosystems,
Foster City, CA, USA). Q-PCR was performed by using
the ABI Prism 7000 sequence detection system (Applied
Biosystems) for an amount of 10 ng cDNA with SYBR
Green Master mix. Quantification of the PCR signals
was performed by comparing the cycle threshold value
(Ct) of the gene of interest of each sample with the Ct
values of the reference gene GAPDH (ΔCt), and
expressed as 2-ΔCt multiplied by arbitrary factor. Fold
change was calculated as the mean ratio between the
relative transcript levels. The sequences of primer sets
used were as follows: 5’-TTCCCCATGGTGTCTGAGC-
3’ (GAPDH forward), 5’-ATCTTCTTTTGCGTCGC-
CAG-3’ (GAPDH reverse), 5’-TGACTCCTAC-
CAAAGCTGTCAAAAC-3’ (dectin-1 forward), and 5’-
TTCTCATATATAATCCAATTAGGAGGACAAG-3’
(dectin-1 reverse).
Immunohistochemical staining in synovial tissue
In specimens obtained from knee surgery, dectin-1 pro-
tein expression was evaluated by immunohistochemical
staining in paraffin-embedded inflamed synovial tissue
sections of RA patients. The applied primary antibody
was a monoclonal mouse-anti-human dectin-1 antibody
(MAB 1859, purchased from R&D Systems, Minneapo-
lis, MN, USA), used in a concentration of 5 μg/ml. After
overnight incubation with the primary antibody, the
tissue sections were incubated for 1 h with a secondary
antibody after washing with PBS. Subsequently, the
staining was visualised by applying ABC complex and
DAB solution. Sections were counterstained with hae-
matoxylin. Staining with a mouse IgG2b isotype control
antibody served as a negative control.
In vitro macrophage stimulation assays
PBMCs were obtained from healthy donors, either wild-
type or heterozygous for the Y238X polymorphism.
Cells homozygous for the DECTIN-1 Y238X poly-
morphism were obtained from three members of a
family previously analyzed for mucocutaneous Candida
infections [22]. PBMCs were isolated from peripheral
blood as described previously [11]. The PBMC fraction
was plated in flat-bottom 96-well plates. After 4 h of
culture at 37°C, cells were washed 3 times with culture
medium, and the nonadherent cells were removed. The
adherent monocytes were cultured for 6 days in culture
medium with 10% heat-inactivated pooled human
serum, until the monocytes exhibited macrophage-like
morphology and expressed characteristic surface mar-
kers analyzed with flow cytometry. On day 6 of culture,
after washing 3 times with fresh medium, macrophages
were stimulated for 24 h with b-glucan (10 μg/ml),
Pam3Cys (10 μg/ml), or with a combination of the two
stimuli. Cytokine production was measured with ELISA
(purchased from R&D Systems) according to the guide-
lines of the manufacturer. Detection levels were 10 pg/
ml for TNF-a and 20 pg/ml for IL-1b.
Genotyping for DECTIN-1 Y238X polymorphism
Genomic DNA was isolated from peripheral venous
blood by using standard techniques and stored at 4°C.
Genotyping for the presence of the Y238X polymorph-
ism in exon 6 of the DECTIN-1 gene (also known as
CLEC7A) in the patient and in healthy control groups
was performed by applying the predesigned TaqMan
SNP assay C_33748481_10 on the 7300 ABI Real-Time
PCR system (both from Applied Biosystems). We
declare that all the subjects included in this study were
prospectively asked to provide consent in regard to the
use of clinical data as well as DNA samples for future
investigations. All patients gave informed consent, as
required by our local ethics committee and in accor-
dance with the Declaration of Helsinki.
Statistics
Statistical analysis for the oligonucleotide array-based
gene expression was performed by using dChip. The t
statistic was computed as (mean1 - mean2)/
SE mean SE mean( ) ( )1 22 2 ); its value is computed
based on the t distribution, and the degree of freedom is
set according to Welch modified two sample t test [28].
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Statistical analysis of the gene expression data obtained
by quantitative PCR and of the cytokine measurements
obtained with ELISA was performed by applying the
Mann Whitney U test.
Concerning the correlation of the DECTIN-1 genotype
with clinical RA parameters, the following statistical
tests were applied. Between-group differences between
DECTIN-1 wild-type and heterozygous patients were
analyzed by using a c2 test, a t test or a Wilcoxon test,
as appropriate. To test the effect of the DECTIN-1 geno-
type on the progression of joint damage, for every
patient, the annual joint-damage progression rate was
calculated by subtracting the last available joint damage
score from the baseline joint damage score, and dividing
the joint damage progression by follow-up time. The
difference between wild-type and heterozygous patients
was tested by using a linear regression model with
uptake of confounders. Regression assumptions were
tested by using residual plots and predicted-versus-
observed plots. The analysis was repeated by using long-
itudinal regression analysis (mixed models), by using all
available data while correcting for repeated measure-
ments within patients.
For all statistical analyses, a P value < 0.05 was consid-
ered significant.
Results
Dectin-1 mRNA and protein expression in synovial tissue
To gain insight into the distribution and amount of dec-
tin-1 expression in human synovial tissue, dectin-1
mRNA expression was measured in synovial tissue from
RA, OA, and nonrheumatic patients with an oligonu-
cleotide array and reevaluated with quantitative PCR.
Microarray analysis revealed a 4-times elevated mRNA
expression in RA synovial lesions compared with OA
and nonrheumatic synovial tissues (Figure 1a). These
findings were confirmed with quantitative PCR (Figure
1b). Furthermore, synovial biopsies from RA patients
were immunohistochemically stained for dectin-1 pro-
tein expression. Dectin-1 protein appeared to be moder-
ately to highly expressed in RA lesions and was
preferentially expressed on the membranes of macro-
phage-like cells that infiltrated into the synovial tissue,
which were present in the synovial sublining and in
close proximity to blood vessels (Figure 2).
In vitro macrophage stimulation assays
Because especially macrophages are known to express
dectin-1 in high amounts and are possibly involved in RA
pathogenesis, we analyzed the functional consequences
of the DECTIN-1 Y238X polymorphism for the inflam-
matory response of these cells with dectin-1 stimulation.
Monocytes were differentiated into macrophages in vitro
and were stimulated for 24 hours with b-glucan, the
TLR2 agonist Pam3Cys, and both ligands simultaneously.
After stimulation with b-glucan, cytokine measurements
revealed a diminished TNF-a and IL-1b production
capacity in cells from individuals homozygous for the
Y238X polymorphism compared with cells from wild-
type individuals. In cells from heterozygous individuals,
these responses were intermediate. Moreover, the pre-
viously described synergy between dectin-1 and TLR2
induced responses [11,12] regarding TNF-a and IL-1b
production was abolished in cells isolated from indivi-
duals with the polymorphism. The TLR2/dectin-1 syner-
gism was reduced in cells isolated from heterozygous
individuals and was completely absent in cells obtained
from individuals homozygous for the Y238X polymorph-
ism compared with the individuals bearing only the wild-
type DECTIN-1 allele (Figure 3).
Genotyping of RA patients compared with healthy
controls
To assess whether the DECTIN-1 Y238X polymorphism
is associated with an altered susceptibility to RA, a cohort
of 262 RA patients and a cohort of healthy individuals (n
= 284) were screened for the presence of the polymorph-
ism. The allele frequency of the polymorphism was 7.8%
in the RA cohort, compared with 7.6% in the cohort of
healthy individuals (P = 0.87). All individuals bearing the
polymorphism were heterozygous (Table 1).
Effects of DECTIN-1 genotype on clinical parameters of
rheumatoid arthritis
The clinical data of the 262 cohort patients are shown in
Table 2. At the different time points, no differences were
seen in joint damage and a tendency for higher DAS28
values between the patients with a heterozygous or wild-
type DECTIN-1 genotype. Follow-up time was similar in
both genotype groups; 50% were followed up for 9 years,
whereas 70% were followed up for at least 6 years. The
mean annual joint damage progression rate was 3.33 per
year in patients bearing the wild-type DECTIN-1 com-
pared with 3.38 per year in patients heterozygous for the
DECTIN-1 Y238X allele. The uncorrected between-group
difference was nearly zero, with an estimated mean
annual joint damage progression of 0.05 with P = 0.95
(Table 3). When corrected for joint damage at baseline,
rheumatoid factor positivity, and the average DAS28 as
possible confounders, the between-group difference
remained insignificant (P = 0.57). Regression assumptions
were met. The results of the longitudinal regression ana-
lysis (mixed models) were not different (not shown).
Discussion
Rheumatoid arthritis (RA) is a systemic, chronic inflam-
matory disorder with autoimmune characteristics that
affects 0.5% to 1.0% of the Western population. RA
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causes progressive cartilage damage and often concomi-
tant bone destruction, which tremendously impairs joint
movement. It is generally accepted that a complex inter-
play of genetic and environmental factors contributes to
the etiology of RA.
Dectin-1, a member of the C-type lectin receptor
family and the main b-glucan receptor, was recently
demonstrated to be involved in promoting pro-inflam-
matory responses. Dectin-1 synergizes with TLR
signalling pathways [11,12] and contributes to induction
of T-cell responses, including Th17 [14,29]. Several ani-
mal models of experimentally induced arthritis have
been shown to be induced or exacerbated by administer-
ing fungal-derived particles such as zymosan and glu-
cans that can be recognized by and signal through
dectin-1. Moreover, a more specific role for dectin-1 in
RA pathogenesis has been investigated in arthritis-prone
SKG mice, in which b-glucan induced arthritis could be
Figure 1 (a) Dectin-1 mRNA expression of human synovial tissue obtained from six nonrheumatic control individuals, 20 rheumatoid
arthritis patients (RAs), and 10 osteoarthritis patients (OAs). Dectin-1 mRNA expression was analyzed with oligonucleotide array (Affymetrix
system). Values represent computed expression values. (b) Confirmation of microarray data by qPCR. Data are based on four control samples,
seven samples obtained from RA patients, and 6 samples from OA patients. Relative expression is depicted compared with expression of the
housekeeping gene GAPDH. Data are expressed as mean ± SD; *P ≤ 0.05; n.s., not significant.
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Figure 2 Immunohistochemical staining for dectin-1 on paraffin-embedded synovial tissue specimens obtained from rheumatoid
arthritis (RA) patients. Pictures are representative of staining on synovial tissue biopsies from five patients. (a, b) anti-dectin-1 staining; (c)
isotype control antibody. Original magnification: (a and c) 200×; and (b) 400×.
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Figure 3 Cytokine production capacity of TNF-a (a) and IL-1b (b) after stimulation of monocyte derived macrophages during 24 hours
with b-glucan, Pam3Cys, or b-glucan/Pam3Cys. Cells were obtained from individuals with the wild-type (WT, n = 6), heterozygous (HET, n =
4), and homozygous (HOM, n = 4) for the DECTIN-1 Y238X polymorphism. Cytokine concentrations were determined with enzyme-linked
immunosorbent assay (ELISA). Data are expressed as mean values ± SD, *P ≤ 0.05.
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prevented by competitively blocking the dectin-1 recep-
tor [20].
Very recently, the functional consequences of the
Y238X early stop codon polymorphism in DECTIN-1
have been studied in detail. This polymorphism was
demonstrated to result in a complete loss of function of
the protein to bind b-glucan, and, as a consequence,
cells homozygous for this polymorphism are unable to
induce intracellular signalling and subsequent cytokine
production on exposure to b-glucans [21,22].
In this study, dectin-1 and the DECTIN-1 polymorph-
ism Y238X (c.714T>G, rs16910526) were examined con-
cerning their role in RA pathogenesis. Dectin-1 mRNA
expression was measured with an oligonucleotide
expression array and confirmed with quantitative PCR
in synovial tissue biopsies from RA patients and com-
pared with OA and nonrheumatic synovial tissue. Dec-
tin-1 mRNA expression was fourfold higher in RA
synovial tissue, compared with synovial tissues obtained
from OA, in which immune mechanisms are minimally
involved, and from nonrheumatic patients. Dectin-1 pro-
tein expression in RA synovial tissue was shown to be
moderate to high, mostly located on infiltrating macro-
phage-like cells residing in the synovial sublining and
around blood vessels. This indicates that dectin-1 is pre-
sent in high amounts in RA synovial tissue and there-
fore can contribute to the inflammatory response
exerted by macrophages in this setting.
Subsequently, because dectin-1 appeared to be highly
expressed on infiltrating macrophages, the consequences
of the DECTIN-1 Y238X polymorphism for dectin-1
mediated cytokine production capacity of macrophages
were studied. Macrophages from individuals bearing the
DECTIN-1 polymorphism exhibited an impaired capa-
city to produce cytokines induced by dectin-1 signalling.
Table 1 Genetic distribution of the DECTIN-1 Y238X polymorphism in a patient cohort of rheumatoid arthritis (n =
262) and in a group of healthy controls (n = 284)
DECTIN-1 genotype Allele frequency
Cohort Wild-type Heterozygous Homozygous Wild-type Derived
RA (n = 262) 84.4% (221) 15.6% (41) 0 92.2% 7.8%
Controls (n = 284) 84.9% (241) 15.1% (43) 0 92.4% 7.6%
RA: rheumatoid arthritis.
Table 2 Joint inflammation and bone destruction
Variable n Homozygous wild-type
for DECTIN-1
n Heterozygous for
DECTIN-1 Y238X
P value
Age (years) 221 53 (14) 41 53 (13) 0.87
Female 221 147 (66%) 41 25 (61%) 0.49
Rheumatoid factor + 220 163 (74%) 41 34 (83%) 0.23
DAS28 baseline 212 5.2 (1.5) 40 5.3 (1.4) 0.55
Average DAS28 year 0-3 214 3.9 (1.1) 41 4.1 (1.2) 0.37
Average DAS28 year 4-6 203 3.5 (1.1) 35 3.9 (1.3) 0.05
Average DAS28 year 7-9 166 3.5 (1.2) 28 4.0 (1.3) 0.07
Joint-damage score baseline 221 0 (0-2) 41 0 (0-3) 0.87
Joint-damage score year 3 221 6 (1-15) 41 5 (0-18) 0.70
Joint-damage score year 6 154 13 (2-26) 29 14 (3-26) 0.98
Joint-damage score year 9 109 20 (8-35) 24 20 (3-37) 0.98
DAS28: Disease Activity Score using 28 joint counts. Baseline and follow-up values of disease markers of joint inflammation and bone destruction of 262 RA
patients, stratified by DECTIN-1 genotype. Values are numbers (percentage), medians (p25-p75) or means (SD), as indicated by the notation.
Table 3 Between-group differences for DECTIN-1 Y238X
genotype in joint-damage progression
Parameter Estimate SE P value
Intercept 3.32 0.32 < 0.0001
DECTIN-1 genotype 0.05 0.79 0.95
Intercept 1.07 0.58 0.065
DECTIN-1 genotype -0.40 0.71 0.57
Joint damage at baseline 2.65 0.53 < 0.0001
Rheumatoid factor + 1.28 0.63 0.043
Average DAS28a 1.26 0.24 < 0.0001
DAS28: Disease Activity Score using 28 joint counts. Results of the linear
regression model with 262 RA patients. The upper model tests the difference
in annual joint-damage progression rate between wild-type patients and
patients heterozygous for the DECTIN-1 Y238X polymorphism, indicated by
the estimate of DECTIN-1 genotype (P = 0.95). The lower model tests the same
(P = 0.57), with addition of baseline joint damage, rheumatoid factor
positivity, and the time-averaged DAS28 as confounders. aTime-averaged
DAS28 was centered.
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This was demonstrated for TNF-a and IL-1b, both cru-
cial cytokines in RA pathogenesis [30,31].
Considering the important consequences for the func-
tion of the protein, we analyzed whether the presence of
the DECTIN-1 Y238X polymorphism is correlated with
the susceptibility to and clinical severity of RA in a
Dutch cohort of 262 RA patients. An overall allele fre-
quency of 7.8% was obtained and was not significantly
different compared with that in a healthy control group
(n = 284) with an allele frequency of 7.6% (P = 0.87;
Table 1). All individuals tested were heterozygous for
the polymorphism. The correlation of clinical para-
meters, that is, inflammation markers and degree of
bone destruction, also revealed no statistically significant
differences (Table 2). Finding no difference in bone
destruction in RA patients homozygous and heterozy-
gous for the DECTIN-1 Y238X polymorphism could
also be a problem of statistical power. However, the dif-
ference we found was nearly zero. With the group sizes
we obtained, adopting a two-sided alpha of 0.05, a
“power” of 0.80, and an SD of 3 in the usual power cal-
culation formula, we would have been able to detect a
difference in annual joint damage progression in a
Ratingen score of 1.5, which we regard as reasonably
small.
Conclusions
These data imply that, despite the lower cytokine
responses exhibited by individuals heterozygous for the
DECTIN-1 Y238X polymorphism on stimulation with
dectin-1, partial dectin-1 deficiency has a major influ-
ence neither on disease susceptibility nor on the degree
of inflammation and bone destruction in RA patients.
Whether homozygosity for the DECTIN-1 Y238X poly-
morphism may result in a different susceptibility to RA
remains to be investigated in studies large enough to
identify the rare homozygous individuals.
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